tradingkey.logo

Johnson & Johnson - Tremfya Phase 3B Study Achieves Primary And Secondary Endpoints

ReutersApr 4, 2025 12:06 PM

- Johnson & Johnson JNJ.N:

  • TREMFYA® (GUSELKUMAB) IS THE FIRST AND ONLY IL-23 INHIBITOR TO SIGNIFICANTLY REDUCE BOTH THE SIGNS AND SYMPTOMS AND THE PROGRESSION OF STRUCTURAL DAMAGE IN ADULTS LIVING WITH ACTIVE PSORIATIC ARTHRITIS

  • JOHNSON & JOHNSON - TREMFYA PHASE 3B STUDY ACHIEVES PRIMARY AND SECONDARY ENDPOINTS

  • JOHNSON & JOHNSON - TREMFYA SAFETY PROFILE CONSISTENT WITH NO NEW SAFETY SIGNALS

  • JOHNSON & JOHNSON - TREMFYA SHOWS LESS STRUCTURAL DAMAGE PROGRESSION AT WEEK 24

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI